Adiponectin and Insulin Resistance in Diabetic Nephropathy
NCT ID: NCT00774904
Last Updated: 2008-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2007-04-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
NCT00361023
Steroid Diabetes in Patients With Kidney Disease
NCT06161701
Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension
NCT00407680
Pioglitazone and Losartan Provides Additional Renoprotection
NCT00364988
Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy
NCT02690883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Losartan
Angiotensin II Type 1 Receptor Blockers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CKD at stage 1\~4
Exclusion Criteria
* An elevated plasma K level.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Xi'an Jiaotong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
shanghai No 3 people's hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai No.3 people's hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pan Y, Qiao QY, Pan LH, Zhou DC, Hu C, Gu HF, Fu SK, Liu XL, Jin HM. Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Exp Clin Endocrinol Diabetes. 2015 Mar;123(3):170-7. doi: 10.1055/s-0034-1395658. Epub 2014 Dec 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADPN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.